A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Clinical trial NCT04035434 · TERMINATED

Trial details

NCT number: NCT04035434
Sponsor: CRISPR Therapeutics AG
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Malignancy Non-Hodgkin Lymphoma B-cell Lymphoma Adult B Cell ALL

Start date: 2019-07-22
Primary completion: 2024-10-04
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.